2nd
October
2019
Written by Sam Ricchezza
In line with this, the pharmaceutical industry is seeing a shift to develop modified release dosage forms that can deliver more therapeutic value and better outcomes for different groups, such as pediatric and geriatric patients.
Bora's Business Development Department spoke to Pharmaceutical Technology Europe to discuss some of the key challenges impacting the pharmaceutical development pipeline and the importance of a continued patient-centric approach.
For the full article, see: http://www.pharmtech.com/demands-perfect-dose